Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Cash: 2016-2025

Historic Change in Cash for Summit Therapeutics (SMMT) over the last 8 years, with Sep 2025 value amounting to -$59.3 million.

  • Summit Therapeutics' Change in Cash fell 190.77% to -$59.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.8 million, marking a year-over-year increase of 105.92%. This contributed to the annual value of $33.8 million for FY2024, which is 105.85% up from last year.
  • Summit Therapeutics' Change in Cash amounted to -$59.3 million in Q3 2025, which was down 168.69% from $86.3 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Change in Cash high stood at $526.6 million for Q4 2022, and its period low was -$577.6 million during Q1 2023.
  • Moreover, its 3-year median value for Change in Cash was -$9.8 million (2024), whereas its average is -$37.2 million.
  • In the last 5 years, Summit Therapeutics' Change in Cash spiked by 6,327.22% in 2022 and then crashed by 10,307.42% in 2023.
  • Summit Therapeutics' Change in Cash (Quarterly) stood at -$8.5 million in 2021, then surged by 6,327.22% to $526.6 million in 2022, then slumped by 90.96% to $47.6 million in 2023, then plummeted by 76.72% to $11.1 million in 2024, then slumped by 190.77% to -$59.3 million in 2025.
  • Its Change in Cash was -$59.3 million in Q3 2025, compared to $86.3 million in Q2 2025 and $106.7 million in Q1 2025.